Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:40 PM
Ignite Modification Date:
2025-12-24 @ 5:40 PM
NCT ID:
NCT00087568
Eligibility Criteria:
Inclusion Criteria:
* adult patients at least 18 years of age
* CHC infection, genotype 1
* unable to tolerate or not responsive to PEG-Intron + ribavirin therapy after 12 weeks of treatment
* use of 2 forms of contraception during the study in both men and women
Exclusion Criteria:
* women who are pregnant or breast-feeding
* medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)
* patients with decompensated cirrhosis
* patients receiving any systemic antiviral therapy or investigational drug, other than PEG-Intron + ribavirin, 24 weeks prior to the first dose of study drug
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00087568
Study Brief:
Protocol Section:
NCT00087568